Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 2/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 7/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 4/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | MMP12 | P39900 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7282954 | 0.80 | AR (0.49) | MMP3CYP11B2GRM2AR | |
| SCHEMBL4421994 | 0.76 | MMP3 (0.44) | MMP3CYP11B2GRM2AR | |
| SCHEMBL2789041 | 0.75 | GLRA3 (0.49) | MMP3SLC22A12MAP4K4GRM2PTGER4 | |
| SCHEMBL2744074 | 0.74 | LTB4R2 (0.46) | SLC22A12MAP4K4XDH | |
| SCHEMBL5370251 | 0.73 | HTT (0.49) | MMP3SLC22A12MAP4K4MMP2CYP11B2 | |
| SCHEMBL28674680 | 0.72 | ALDH1A1 (0.48) | XDH | |
| SCHEMBL2788974 | 0.72 | CA1 (0.41) | — | |
| SCHEMBL27245981 | 0.72 | MMP3 (0.48) | MMP3 | |
| SCHEMBL6644495 | 0.71 | SLC22A12 (0.56) | SLC22A12MAP4K4XDHAR | |
| SCHEMBL29290463 | 0.71 | MMP2 (0.48) | MMP3MMP2MMP9PTGER4MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041657-A1 | HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDICK A/S (DK) | 2010-02-18 | — | — | US | claimed |
| EP-1881961-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDISK A/S (DK) | 2008-01-30 | — | — | EP | claimed |
| WO-2006120178-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDISK A/S (DK) | 2006-11-16 | — | — | WO | claimed |
| US-20100041657-A1 | HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDICK A/S (DK) | 2010-02-18 | — | — | US | disclosed |
| EP-1881961-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDISK A/S (DK) | 2008-01-30 | — | — | EP | disclosed |
| WO-2006120178-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDISK A/S (DK) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041657-A1 | HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | RPS12, GPR119, ATP12A | MMP3 2466/4885SLC22A12 440/4885MAP4K4 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.